Xifaxan Ibsd denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xifaxan ibsd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Xifaxan (rifaximin) in IBS-D

Prior authorization (PA) for Xifaxan in IBS-D is standard practice at UnitedHealthcare. UHC requires pre-approval to confirm the diagnosis is appropriate, that required prior therapies have been tried, and that clinical severity meets their coverage criteria. A PA denial — as opposed to a retroactive coverage denial — means the request was submitted but not approved before the prescription was dispensed, or the authorization request was denied outright. In either case, the appeal pathway is well-established.

## Your Appeal Rights

• Internal appeal: Under ERISA §503, employer-sponsored plans must provide a full-and-fair internal review of any adverse benefit determination, including PA denials.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review. File within the four-month window from the final internal denial. The external reviewer's decision is binding.
• Expedited review: If you are currently experiencing significant symptoms and delay would cause harm, request expedited processing — typically resolved within 72 hours.
• Peer-to-peer review: Before or alongside a formal appeal, the prescribing clinician may request a peer-to-peer call with UHC's reviewing medical director. This is often the fastest path to an authorization reversal.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, symptom history, and the ICD-10 code confirming IBS-D. 2. Prior-treatment history with dates and outcomes — a chronological list of every treatment tried before Xifaxan, including start/stop dates and the reason each was stopped. 3. Clinical severity documentation — office notes, patient-reported outcome measures, or functional-status documentation showing the burden of the condition. 4. FDA prescribing label — confirm the IBS-D indication is approved and attach the label. 5. UHC prior-authorization criteria — request the current PA criteria from UHC before filing; address each criterion explicitly in the appeal letter. 6. Prescriber medical-necessity letter — individualized, signed, with specific reference to UHC's PA criteria and the patient's chart findings.

## Criteria-Mapping Structure

PA appeals succeed most reliably when the appeal letter reproduces each authorization criterion and answers it with a specific chart fact:

| UHC PA Criterion | Supporting Chart Documentation | |---|---| | Confirmed IBS-D diagnosis | Chart note [date], ICD-10 code | | Step-therapy requirement met | Dated prior-treatment list, pharmacy records | | Prescriber attestation of medical necessity | Attached prescriber letter |

Keep a copy of the full submission package and note all submission dates and reference numbers in case you need to escalate to external review.